Current model of the blood coagulation cascade, depicting NOACs’ mechanism of action

The current model of the blood coagulation cascade, depicting NOACs’ mechanism of action. There are two pathways, the intrinsic pathway and the extrinsic pathway. These multicomponent processes are illustrated as enzymes, inhibitors, zymogens, or complexes. On injury to the vessel wall, tissue factor, the cofactor for the extrinsic tenase complex, is exposed to circulating FVIIa and forms the extrinsic tenase. FIX and FX are converted to their serine proteases FIXa and FXa, which then form the intrinsic tenase and the prothrombinase complexes, respectively. The combined actions of the intrinsic and extrinsic tenase and the prothrombinase complexes lead to an explosive burst of the enzyme thrombin (IIa). In addition to its multiple procoagulant roles, thrombin also acts in an anticoagulant capacity when combined with the cofactor thrombomodulin in the protein Case complex. The product of the protein Case reaction, activated protein C (APC), inactivates the cofactors FVa and FVIIIa. The cleaved species, FVai and FVIIIai, no longer support the respective procoagulant activities. Once thrombin is generated through procoagulant mechanisms, thrombin cleaves fibrinogen (releasing fibrinopeptide A and B [FPA and FPB]), as well as activating FXIII to form a cross-linked fibrin clot. Thrombin–thrombomodulin also activates thrombin activate-able fibrinolysis inhibitor, which slows fibrin degradation by plasmin. The procoagulant response is downregulated by the stoichiometric inhibitor tissue factor pathway inhibitor (TFPI) and antithrombin III (AT-III). TFPI serves to attenuate the activity of the extrinsic tenase trigger of coagulation. AT-III directly inhibits thrombin, FIXa, and FXa. The accessory pathway provides an alternate route for the generation of FIXa. Thrombin has also been shown to activate FXI. The fibrin clot is eventually degraded by plasmin, yielding soluble fibrin peptides. Factor Xa inhibitors (apixaban, edoxaban, and rivaroxaban) act by binding to the active site of factor Xa, inhibiting the conversion of prothrombin to thrombin, the final enzyme in the coagulation cascade. Dabigatran, conversely, functions as a direct thrombin inhibitor. It binds with high affinity to the active site of thrombin, inhibiting its ability to convert fibrinogen to fibrin, thereby preventing clot formation
Current model of the blood coagulation cascade, depicting NOACs’ mechanism of action

Publication

Beyond Anticoagulation: A Comprehensive Review of Non-Vitamin K Oral Anticoagulants (NOACs) in Inflammation and Protease-Activated Receptor Signaling (2024) Shirin Jannati, et al. Int J Mol Sci. 2024 Aug;25(16). Figure: F1.

Gene mentions


Organism Group Word Match Source NCBI Symbol NCBI ID
Homo sapiens Primates HMW HMW ncbigene_synonym CFAP97 57587
Homo sapiens Primates Xla XLA ncbigene_synonym BTK 695
Homo sapiens Primates AT-III ATIII ncbigene_synonym SERPINC1 462
Homo sapiens Primates AT-III AT3 ncbigene_synonym ATXN3 4287
Homo sapiens Primates AT-III AT3 ncbigene_synonym PGR-AS1 101054525
Homo sapiens Primates TFPI TFPI ncbigene_symbol TFPI 7035
Homo sapiens Primates Fibrinogen FIBRINOGEN famplex_relations FGA 2243
Homo sapiens Primates Fibrinogen FIBRINOGEN famplex_relations FGB 2244
Homo sapiens Primates Fibrinogen FIBRINOGEN famplex_relations FGG 2266
Homo sapiens Primates PAI-1 PAI-1 ncbigene_synonym SERPINE1 5054
Homo sapiens Primates Plasmin PLG ncbigene_symbol PLG 5340
Homo sapiens Primates APC APC ncbigene_symbol APC 324
Homo sapiens Primates APC APC ncbigene_synonym PROC 5624
Homo sapiens Primates TAFI TAFI ncbigene_synonym CPB2 1361
Homo sapiens Primates TAFI TAFI ncbigene_synonym SET 6418

Chemical mentions

Word Match MeSH Name ChEBI
Ca2+ Ca2+ Ca(2+) chebi:29108
Factor X Factor X chebi:4964
Ca2+ Ca2+ Ca(2+) chebi:29108
Factor X Factor X chebi:4964
Apixaban apixaban 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide chebi:72296
Edoxaban edoxaban 4-methylbenzene-1-sulfonic acid--N(1)-(5-chloropyridin-2-yl)-N(2)-{(1S,2R,4S)-4-(dimethylcarbamoyl)-2-[(5-methyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl}ethanediamide--water (1/1/1) chebi:85974
Thrombin Thrombin chebi:9574
Dabigatran dabigatran chebi:70752
Prothrombin Prothrombin chebi:8583
Ca2+ Ca2+ Ca(2+) chebi:29108
Rivaroxaban rivaroxaban 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide chebi:68579
Inhibitors inhibitors inhibitor chebi:35222
Inhibitors inhibitors inhibitor chebi:35222
Thrombin Thrombin chebi:9574
Inhibitor inhibitor inhibitor chebi:35222
Fibrin Fibrin chebi:5054
Thrombin Thrombin chebi:9574
Ca2+ Ca2+ Ca(2+) chebi:29108

Disease mentions

Word Match MeSH Name DOID